Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Proteomic Analysis of Urinary Extracellular Vesicles for the Diagnosis of Prostate Cancer

By LabMedica International staff writers
Posted on 30 Apr 2020
A new method for diagnosis of prostate cancer relies on advanced proteomics-based analysis of extracellular vesicles isolated from urine samples.

Extracellular vesicles (EVs) are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. More...
The vesicles, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane.

EVs are increasingly being recognized as important vehicles of communication between cells and as promising diagnostic and prognostic biomarkers in cancer. Despite the huge clinical potential, the wide variety of methods for separating EVs from biofluids, which provide material of highly variable purity, and the lack of knowledge regarding methodological reproducibility have impeded the entry of EVs into the clinical arena.

In an effort to increase the usefulness of EVs, investigators at Ghent University (Belgium) and colleagues at the University of Turku (Finland) used mass spectrometry-based proteomics to analyze EVs that had been separated and purified from urine by a novel procedure. This density-based fractionation of urine samples obtained from men with benign and malignant prostate disease by bottom-up Optiprep (the iodine-containing non-ionic radiocontrast agent iodixanol) density gradient centrifugation separated EVs and soluble proteins with high specificity and repeatability.

The investigators reported that differential quantitative proteomic analysis of EV-enriched and protein-enriched urine fractions identified unique and biologically and clinically relevant proteomes in urinary EVs. In addition, by profiling matched prostate cancer tissue-derived EVs and urinary EVs, they demonstrated that the urinary EV proteome was a reflection of that of EVs derived from the tissue of origin.

“Detecting and examining these vesicles in urine has an enormous potential for developing new tests for early detection of urological cancers. However, research related to this is still in its infancy,” said first author Bert Dhondt, a researcher in the laboratory for experimental cancer research at Ghent University. “In the future, the results of the study can aid patients with urological cancers through faster diagnosis and timely treatment.”

The proteomic analysis of EVs in the urine of prostate cancer patients was described in the March 11, 2020, online edition of Journal of Extracellular Vesicles.

Related Links:
Ghent University
University of Turku



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.